A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.
Breast Cancer
DRUG: ARV-471|DRUG: ARV-471 in combination with palbociclib (IBRANCE®)
Part A: Incidence of Dose Limiting Toxicities of ARV-471, First Cycle Dose limiting toxicities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug, 28 Days|Part A: Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-471, Adverse events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug., First study drug dose through a minimum of 30 calendar Days After Last study drug administration|Part A: Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-471, Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing., First study drug dose through a minimum of 30 calendar Days After Last study drug administration|Part B: Assessment of anti-tumor activity of ARV-471, Clinical benefit response rate based on the summation of CRs, PRs and stable disease of 24 weeks duration or longer, through study completion, up to approximately 2 years|Part C: Incidence of Dose Limiting Toxicities of combination ARV-471 + palbociclib, First cycle dose-limiting toxicities and determination of a maximum tolerated dose (MTD) if applicable among the doses evaluated, 28 Days|Part C: Number of Patients with Adverse Events as a measure of safety and tolerability of combination ARV-471 + palbociclib, Adverse events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug combination, First study drug dose through a minimum of 30 calendar Days After Last study drug administration|Part C: Incidence of laboratory abnormalities as a measure of safety and tolerability of combination ARV-471 + palbociclib, Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing, First study drug dose through a minimum of 30 calendar Days After Last study drug administration
Part A: Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC)., Concentration-time curve (AUC) for single and multiple dose of ARV-471 PK parameters will be assessed when applicable after a single dose and after multiple doses., At predefined intervals throughout the ARV-471 treatment period, up to approximately 4 weeks after last dose of ARV-471|Part A: Assessment of pharmacokinetic parameter maximum concentration (Cmax)., Maximum concentration (Cmax) for single and multiple dose of ARV-471 PK parameters will be assessed when applicable after a single dose and after multiple doses., At predefined intervals throughout the ARV-471 treatment period, up to approximately 4 weeks after last dose of ARV-471|Part A: Assessment of pharmacokinetic parameter minimum concentration (Cmin)., Minimum concentration (Cmin) for single and multiple dose of ARV-471 PK parameters will be assessed when applicable after a single dose and after multiple doses., At predefined intervals throughout the ARV-471 treatment period, up to approximately 4 weeks after last dose of ARV-471|Part A: Assessment of pharmacokinetic parameter time to maximum concentration (Tmax)., Time to maximum concentration (Tmax) for single and multiple dose of ARV-471 PK parameters will be assessed when applicable after a single dose and after multiple doses., At predefined intervals throughout the ARV-471 treatment period, up to approximately 4 weeks after last dose of ARV-471|Part A: Assessment of anti-tumor activity of ARV-471, Anti-tumor activity of ARV-471 will be assessed by evaluating overall response rate per RECIST 1.1., through study completion, up to approximately 2 years|Part A: Assessment of anti-tumor activity of ARV-471, Anti-tumor activity of ARV-471 will be assessed by evaluating clinical benefit response (CBR) rate based on the summation of complete responses (CRs), partial responses (PRs) and stable disease of 24 weeks duration or longer., through study completion, up to approximately 2 years|Part A: Assessment of anti-tumor activity of ARV-471, Anti-tumor activity of ARV-471 will be assessed by evaluating disease control rate (complete response, partial response, stable disease)., through study completion, up to approximately 2 years|Part A: Assessment of anti-tumor activity of ARV-471, Anti-tumor activity of ARV-471 will be assessed by evaluating progression free survival., through study completion, up to approximately 2 years|Part A: Assessment of anti-tumor activity of ARV-471, Anti-tumor activity of ARV-471 will be assessed by evaluating duration of response., through study completion, up to approximately 2 years|Part B: Assessment of anti-tumor activity of ARV-471, Anti-tumor activity of ARV-471 will be assessed by evaluating overall response rate per RECIST 1.1 in patients with measurable disease at baseline., through study completion, up to approximately 2 years|Part B: Assessment of anti-tumor activity of ARV-471, Anti-tumor activity of ARV-471 will be assessed by evaluating duration of response., through study completion, up to approximately 2 years|Part B: Assessment of anti-tumor activity of ARV-471, Anti-tumor activity of ARV-471 will be assessed by evaluating progression-free survival., through study completion, up to approximately 2 years|Part B: Assessment of anti-tumor activity of ARV-471, Anti-tumor activity of ARV-471 will be assessed by evaluating overall survival., through study completion, up to approximately 2 years|Part B: Evaluation of Plasma Concentrations of ARV-471, To characterize the pre-dose concentrations of ARV-471., At predefined intervals throughout the ARV-471 treatment period, up to approximately 4 weeks after last dose of investigational products]|Part B: Evaluation of Safety and Tolerability, Further evaluation of safety and tolerability of ARV-471 will be based on adverse events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug., First study drug dose through a minimum of 30 calendar Days After Last study drug administration|Part B: Evaluation of Safety and Tolerability, Further evaluation of safety and tolerability of ARV-471 will be based on Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing., First study drug dose through a minimum of 30 calendar Days After Last study drug administration|Part C:Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC), Concentration-time curve (AUC) for single and multiple doses of ARV-471 PK parameters will be assessed when applicable after a single dose and after multiple doses, and of palbociclib when given alone and in combination with ARV-471., At predefined intervals throughout the ARV-471 treatment period, up to approximately 4 weeks after last dose of investigational products|Part C: Assessment of pharmacokinetic parameter maximum concentration (Cmax)., Maximum concentration (Cmax) for single and multiple doses of ARV-471 PK parameters will be assessed when applicable after a single dose and after multiple doses, and of palbociclib when given alone and in combination with ARV-471, At predefined intervals throughout the ARV-471 treatment period, up to approximately 4 weeks after last dose of investigational products|Part C: Assessment of pharmacokinetic parameter minimum concentration (Cmin)., Minimum concentration (Cmin) for single and multiple dose of ARV-471 PK parameters will be assessed when applicable after a single dose and after multiple doses., At predefined intervals throughout the ARV-471 treatment period, up to approximately 4 weeks after last dose of investigational products|Part C: Assessment of pharmacokinetic parameter time to maximum concentration (Tmax), Time to maximum concentration (Tmax) for single and multiple dose of ARV-471 PK parameters will be assessed when applicable after a single dose and after multiple doses., At predefined intervals throughout the ARV-471 treatment period, up to approximately 4 weeks after last dose of investigational products|Part C: Assessment of anti-tumor activity of ARV-471 in combination with palbociclib, Anti-tumor activity of ARV-471 in combination with palbociclib will be assessed by evaluating overall response rate per RECIST 1.1 in patients with measurable disease at baseline., through study completion, up to approximately 2 years|Part C: Assessment of anti-tumor activity of ARV-471 in combination with palbociclib, Anti-tumor activity of ARV-471 in combination with palbociclib will be assessed by evaluating clinical benefit response (CBR) rate based on the summation of complete responses (CRs), partial responses (PRs) and stable disease of 24 weeks duration or longer., through study completion, up to approximately 2 years|Part C: Assessment of anti-tumor activity of ARV-471 in combination with palbociclib, Anti-tumor activity of ARV-471 in combination with palbociclib will be assessed by evaluating time to event endpoints: progression free survival, duration of response., through study completion, up to approximately 2 years
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.